LY3177833

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer In Vitro LY3177833 (10 μM; 4 days) increases SA-β-gal content in Hep3B cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Hep3B cells Concentration: 10 μM Incubation Time: 4 days Result: Increased the expression of human SA-β-gal. In Vivo LY3177833 (Example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dose-dependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female athymic Balb/c nude mice (5-6 weeks old) with SW620 cells Dosage: 10.4 mg/kg, 20.8 mg/kg and 31.2 mg/kg Administration: Oral gavage; twice a day for 2 weeks Result: Showed dose dependent antitumor activity in SW620 mouse xenograft tumor model. Form:Solid IC50& Target:Cdc7 3.3 nM (IC 50 ) pMCM2 290 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet